Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Issue 9 (6th September 2022)

• Record Type: Journal Article
• Authors: Bai, Yuping; He, Tingting; Zhang, Liyan; Liu, Qianqian; Yang, Jing; Zhao, Ziru; Yang, Kehu; Zhang, Min
• Is Part Of: BMJ open. Volume 12:Issue 9(2022)
• Publication Date: 2022-09-06
• Subjects: lymphoma -- immunology -- haematology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-060659
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: We aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3 + ) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources of heterogeneity of the results. Design: Systematic review and meta-analysis. Data sources: We searched the Cochrane Library, PubMed, Embase and Web of Science databases up to 5 December 2021. Eligibility criteria: We included studies that analysed the prognostic significance of FOXP3 + Tregs in DLBCL. We included studies reported in Chinese or English that reported HRs and related 95% CIs for prognosis. Data extraction and synthesis: We extracted data from eligible studies. HRs and 95% CIs were used to assess the prognostic value. Results: Fourteen eligible studies were identified. FOXP3 + Treg expression was not associated with overall survival (OS) (HR=0.72, 95% CI 0.45 to 1.16) or progression-free survival (HR=0.86, 95% CI 0.54 to 1.38). The three approaches used to measure FOXP3 + Treg expression (pinteraction <0.001) may be the source of the heterogeneity of the results. Subgroup analysis found that a higher expression of FOXP3 + Tregs was associated with better OS in all populations and in Asians when FOXP3 + Treg expression was measured by the number of positive cells (HR=0.36 (95% CI 0.22 to 0.58) in the former, HR=0.33 (95% CI 0.20 to 0.55) in the latter) or the percentage of positive cells (HR=0.49 (95% CI 0.27 to 0.89) in the former, HR=0.38 (95% CI 0.21 to 0.70) in the latter). However, when measured by the score, inverse results were found (HR=1.56, 95% CI 1.01 to 2.42). Conclusions: Approaches to measuring FOXP3 + Treg expression might be the major source of heterogeneity in studies of the prognostic significance of FOXP3 + Tregs in DLBCL. FOXP3 + Treg expression might be used to predict the prognosis of patients with DLBCL when FOXP3 + Treg expression is calculated by the number or the percentage of positive cells, especially in Asian populations.